toripalimab + gemcitabine + oxaliplatin

Toripalimab + gemcitabine + oxaliplatin is a combination therapy that brings together immunotherapy and chemotherapy for the treatment of advanced cancers, particularly intrahepatic cholangiocarcinoma (ICC). This regimen combines toripalimab, a humanized anti-PD-1 IgG4 monoclonal antibody, with the chemotherapy combination known as GEMOX (gemcitabine plus oxaliplatin). Toripalimab works by blocking the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2, thereby enhancing T-cell immune responses against tumor cells. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA adducts, preventing DNA replication and transcription. In clinical trials, this triple combination has shown promising efficacy and manageable safety profiles for patients with advanced ICC, with objective response rates of up to 80% reported in some studies.

Other names

GEMOX plus toripalimabtoripalimab plus GEMOX